301166 优宁维
已收盘 12-05 15:00:00
资讯
新帖
简况
优宁维:公司2025年开展了9次投资者调研
证券之星 · 12-04
优宁维:公司2025年开展了9次投资者调研
优宁维(301166)披露关于回购公司股份的进展公告,12月01日股价下跌0.53%
证券之星 · 12-01
优宁维(301166)披露关于回购公司股份的进展公告,12月01日股价下跌0.53%
优宁维:累计回购公司股份48300股
证券日报 · 11-03
优宁维:累计回购公司股份48300股
优宁维(301166)2025年三季报简析:净利润同比下降207.11%
证券之星 · 10-31
优宁维(301166)2025年三季报简析:净利润同比下降207.11%
优宁维(301166.SZ)发布前三季度业绩,归母净亏损1507.96万元
智通财经 · 10-29
优宁维(301166.SZ)发布前三季度业绩,归母净亏损1507.96万元
优宁维:已实施两期股份回购计划
证券之星 · 10-28
优宁维:已实施两期股份回购计划
优宁维(301166)披露首次回购公司股份的公告,10月14日股价下跌0.07%
证券之星 · 10-14
优宁维(301166)披露首次回购公司股份的公告,10月14日股价下跌0.07%
优宁维(301166)披露拟续聘2025年度会计师事务所,9月30日股价上涨1.08%
证券之星 · 09-30
优宁维(301166)披露拟续聘2025年度会计师事务所,9月30日股价上涨1.08%
股市必读:优宁维(301166)9月19日披露最新机构调研信息
证券之星 · 09-22
股市必读:优宁维(301166)9月19日披露最新机构调研信息
【机构调研记录】嘉实基金调研皓元医药、优宁维等3只个股(附名单)
证券之星 · 09-17
【机构调研记录】嘉实基金调研皓元医药、优宁维等3只个股(附名单)
优宁维:开源证券、嘉实基金等多家机构于9月16日调研我司
证券之星 · 09-16
优宁维:开源证券、嘉实基金等多家机构于9月16日调研我司
优宁维(301166)2025年中报简析:净利润同比下降188.64%
证券之星 · 08-27
优宁维(301166)2025年中报简析:净利润同比下降188.64%
优宁维(301166.SZ)发布上半年业绩,由盈转亏1337.99万元
智通财经 · 08-25
优宁维(301166.SZ)发布上半年业绩,由盈转亏1337.99万元
优宁维:公司已累计回购927,600股
证券之星 · 08-13
优宁维:公司已累计回购927,600股
优宁维:第三方检测机构为公司客户类型之一
证券之星 · 08-08
优宁维:第三方检测机构为公司客户类型之一
优宁维:公司暂无直接接洽电子通讯半导体行业
互动易 · 08-08
优宁维:公司暂无直接接洽电子通讯半导体行业
优宁维:公司产品主要应用于生命科学科研领域
证券之星 · 08-05
优宁维:公司产品主要应用于生命科学科研领域
优宁维:暂无计划向医药制造端延伸
证券之星 · 08-05
优宁维:暂无计划向医药制造端延伸
优宁维:公司参与投资的股权投资基金主要投向医疗健康、数字经济、先进制造等领域
每日经济新闻 · 08-04
优宁维:公司参与投资的股权投资基金主要投向医疗健康、数字经济、先进制造等领域
优宁维:公司陆续上线ERP系统等信息化系统
证券之星 · 08-04
优宁维:公司陆续上线ERP系统等信息化系统
加载更多
公司概况
公司名称:
上海优宁维生物科技股份有限公司
所属行业:
批发业
上市日期:
2021-12-28
主营业务:
上海优宁维生物科技股份有限公司的主营业务是提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司的主要产品是生命科学试剂、生命科学仪器及耗材、综合技术服务。
发行价格:
86.06
{"stockData":{"symbol":"301166","market":"SZ","secType":"STK","nameCN":"优宁维","latestPrice":31.05,"timestamp":1764918192000,"preClose":30.97,"halted":0,"volume":966922,"delay":0,"changeRate":0.0026,"floatShares":56918700,"shares":86666700,"eps":-0.2194,"marketStatus":"已收盘","change":0.08,"latestTime":"12-05 15:00:00","open":30.97,"high":31.29,"low":30.53,"amount":29841300,"amplitude":0.0245,"askPrice":31.07,"askSize":9,"bidPrice":31.05,"bidSize":11,"shortable":0,"etf":0,"ttmEps":-0.2194,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":30.97,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":34.07,"lowLimit":27.87,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":86666668,"isCdr":false,"pbRate":1.32,"roa":"--","roe":"--","epsLYR":0.12,"committee":0.700758,"marketValue":2691000000,"turnoverRate":0.017,"status":0,"floatMarketCap":1767000000},"requestUrl":"/m/hq/s/301166","defaultTab":"news","newsList":[{"id":"2588407660","title":"优宁维:公司2025年开展了9次投资者调研","url":"https://stock-news.laohu8.com/highlight/detail?id=2588407660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588407660?lang=zh_cn&edition=full","pubTime":"2025-12-04 09:15","pubTimestamp":1764810910,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维(301166)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问:冷总,公司基本上没有机构去调研,也没有券商写研究报告,这就是咱们公司在资本市场的形象,还是董秘工作需要加强改善!优宁维回复:投资者您好,公司2025年开展了9次投资者调研及2次投资者集体接待日活动,具体情况您可关注互动易平台披露的调研记录。谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400005333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2588377688","title":"优宁维(301166)披露关于回购公司股份的进展公告,12月01日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588377688","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588377688?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:39","pubTimestamp":1764599954,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘,优宁维报收于32.16元,较前一交易日下跌0.53%,最新总市值为27.87亿元。该股当日开盘32.33元,最高32.59元,最低32.06元,成交额达2539.66万元,换手率为1.38%。公司近日发布公告,就回购公司股份的进展情况作出说明。根据公告,上海优宁维生物科技股份有限公司于2025年4月10日召开董事会及监事会会议,于2025年5月13日召开股东大会,审议通过回购公司股份方案。本次回购符合相关规定,公司后续将继续实施回购计划并履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100037366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2580546290","title":"优宁维:累计回购公司股份48300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580546290","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580546290?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:09","pubTimestamp":1762168140,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月3日晚间,优宁维发布公告称,截至2025年10月31日,公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份48,300股,占公司总股本的0.06%。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-03/doc-infwcqvf5443279.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-03/doc-infwcqvf5443279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2579045961","title":"优宁维(301166)2025年三季报简析:净利润同比下降207.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579045961","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579045961?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:56","pubTimestamp":1761864995,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期优宁维发布2025年三季报。根据财报显示,优宁维净利润同比下降207.11%。截至本报告期末,公司营业总收入7.76亿元,同比下降6.24%,归母净利润-1507.96万元,同比下降207.11%。按单季度数据看,第三季度营业总收入2.71亿元,同比下降1.45%,第三季度归母净利润-169.97万元,同比下降67.29%。上述因素综合导致公司收入和利润出现下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166"],"gpt_icon":0},{"id":"2579490388","title":"优宁维(301166.SZ)发布前三季度业绩,归母净亏损1507.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579490388","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579490388?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:03","pubTimestamp":1761739439,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)发布2025年三季度报告,该公司前三季度营业收入为7.76亿元,同比减少6.24%。归属于上市公司股东的净亏损为1507.96万元。归属于上市公司股东的扣除非经常性损益的净亏损为3027.45万元。基本每股亏损为0.17元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"优宁维(301166.SZ)发布前三季度业绩,归母净亏损1507.96万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2578952810","title":"优宁维:已实施两期股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2578952810","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578952810?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:51","pubTimestamp":1761655877,"startTime":"0","endTime":"0","summary":"公司非常重视股价波动,致力于通过提升经营业绩并运用股份回购、加强投资者沟通等方式维护公司股价平稳波动。后续公司将会继续运用好股份回购、股权激励等工具,努力提升公司经营质量和业绩,更好地回报投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800040223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2575557212","title":"优宁维(301166)披露首次回购公司股份的公告,10月14日股价下跌0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575557212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575557212?lang=zh_cn&edition=full","pubTime":"2025-10-14 23:00","pubTimestamp":1760454039,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘,优宁维报收于30.47元,较前一交易日下跌0.07%,最新总市值为26.41亿元。该股当日开盘30.65元,最高30.88元,最低30.41元,成交额达2139.39万元,换手率为1.23%。根据公司于2025年10月14日发布的公告,优宁维首次通过回购专用证券账户以集中竞价交易方式回购公司股份。公告指出,本次回购符合相关法律法规及公司回购方案的规定,后续公司将根据市场情况继续实施回购计划,并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400065825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2571336343","title":"优宁维(301166)披露拟续聘2025年度会计师事务所,9月30日股价上涨1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571336343?lang=zh_cn&edition=full","pubTime":"2025-09-30 17:37","pubTimestamp":1759225057,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘,优宁维报收于30.98元,较前一交易日上涨1.08%,最新总市值为26.85亿元。该股当日开盘30.66元,最高31.18元,最低30.49元,成交额达2271.13万元,换手率为1.29%。公司于近日发布公告称,第四届监事会第八次会议于2025年9月28日以现场结合通讯方式召开,审议通过《关于续聘2025年度会计师事务所的议案》,同意续聘立信中联会计师事务所为公司2025年度财务报表及内部控制审计机构。该议案尚需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000029268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2569627816","title":"股市必读:优宁维(301166)9月19日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2569627816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569627816?lang=zh_cn&edition=full","pubTime":"2025-09-22 04:34","pubTimestamp":1758486853,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,优宁维报收于30.98元,下跌1.65%,换手率1.54%,成交量8754.0手,成交额2723.1万元。来自机构调研要点:受毛利率承压及费用投入影响,2025年上半年扣非净利润亏损超2000万元。截至2025年上半年末,杭州抗体研发中心累计研发产品SPU数超4,200个,南京蛋白研发中心累计研发产品SPU数超1,800个。上述因素导致利润下滑。公司高度重视股价波动,已推出两期股份回购计划,将持续关注股价走势并有序推进回购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200001477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2568322014","title":"【机构调研记录】嘉实基金调研皓元医药、优宁维等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568322014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568322014?lang=zh_cn&edition=full","pubTime":"2025-09-17 08:05","pubTimestamp":1758067506,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及9月16日披露的机构调研信息,嘉实基金近期对3家上市公司进行了调研,相关名单如下:1)皓元医药 调研纪要:2025年上半年,公司期间费用共4.10亿元,整体费用率31.25%,同比下降0.76个百分点。2)优宁维 调研纪要:公司自主品牌毛利率约50%,2025上半年收入同比增长超20%,占比持续提升。代理业务毛利率短期承压,长期有望回升;自主品牌毛利率预计稳定,整体毛利水平将逐步上升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700008076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166","688131","BK0216"],"gpt_icon":0},{"id":"2567106379","title":"优宁维:开源证券、嘉实基金等多家机构于9月16日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2567106379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567106379?lang=zh_cn&edition=full","pubTime":"2025-09-16 18:02","pubTimestamp":1758016943,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年9月16日优宁维发布公告称开源证券、嘉实基金于2025年9月16日调研我司。同时随着自主品牌业务收入占比的逐步提升,也有助于公司整体毛利水平逐步升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600028804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250","161027"],"gpt_icon":0},{"id":"2562658557","title":"优宁维(301166)2025年中报简析:净利润同比下降188.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562658557","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562658557?lang=zh_cn&edition=full","pubTime":"2025-08-27 06:34","pubTimestamp":1756247694,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期优宁维发布2025年中报。根据财报显示,优宁维净利润同比下降188.64%。截至本报告期末,公司营业总收入5.05亿元,同比下降8.63%,归母净利润-1337.99万元,同比下降188.64%。按单季度数据看,第二季度营业总收入2.88亿元,同比上升2.7%,第二季度归母净利润-717.12万元,同比下降172.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700009756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166"],"gpt_icon":0},{"id":"2562624599","title":"优宁维(301166.SZ)发布上半年业绩,由盈转亏1337.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562624599","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562624599?lang=zh_cn&edition=full","pubTime":"2025-08-25 19:09","pubTimestamp":1756120185,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)发布2025年半年度报告,报告期内,公司实现营业收入5.05亿元,同比下降8.63%。归属于上市公司股东净亏损1337.99万元。归属于上市公司股东的扣除非经常性损益净亏损2068.35万元。基本每股亏损0.15元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"优宁维(301166.SZ)发布上半年业绩,由盈转亏1337.99万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2559024206","title":"优宁维:公司已累计回购927,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2559024206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559024206?lang=zh_cn&edition=full","pubTime":"2025-08-13 20:51","pubTimestamp":1755089496,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维08月12日在投资者关系平台上答复投资者关心的问题。优宁维回复:投资者您好,为增强投资者信心,维护广大投资者的利益,公司已累计回购927,600股,并于今年4月14日推出了新一期股份回购计划,计划使用1500万-3000万自有资金回购股份,用于注销并减少注册资本。公司上市后每年度进行分红以回馈投资者,截止目前已累计分红超1.8亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300036609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2557541531","title":"优宁维:第三方检测机构为公司客户类型之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2557541531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557541531?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:36","pubTimestamp":1754642169,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维(301166)08月08日在投资者关系平台上答复投资者关心的问题。投资者提问:公司的耗材试剂有供应第三方检测机构吗?优宁维回复:投资者您好,公司主要面向国内高等院校、科研院所、医院和生物医药企业等提供生命科学试剂、设备、耗材、综合技术服务等产品和服务。第三方检测机构为公司客户类型之一,谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800025812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2557541504","title":"优宁维:公司暂无直接接洽电子通讯半导体行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2557541504","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557541504?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:33","pubTimestamp":1754641980,"startTime":"0","endTime":"0","summary":"有投资者向优宁维提问, 贵司参股的领域涉及电子通讯半导体,董事长近期洽谈的这家企业,公司计划准备收购是吗?公司回答表示,投资者您好,公司暂无直接接洽电子通讯半导体行业,谢谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808163602a6da9ca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808163602a6da9ca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["561980","301166","159582","BK0250"],"gpt_icon":0},{"id":"2557874394","title":"优宁维:公司产品主要应用于生命科学科研领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2557874394","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557874394?lang=zh_cn&edition=full","pubTime":"2025-08-05 20:51","pubTimestamp":1754398292,"startTime":"0","endTime":"0","summary":"优宁维回复:投资者您好,公司产品主要应用于生命科学科研领域,该领域客户需求具有广且异的特点,涉及产品非常丰富,公司为此整合了60多家行业知名品牌抗体产品,并与Absin(爱必信)、LabEx(乐备实)、STARTER(斯达特)、UA(优爱)等自主品牌产品,共同形成了以第三方品牌产品为主、自主品牌产品为辅的供应体系,是行业内产品最丰富的企业之一,以满足生命科学客户差异化需求。公司具体产品详见公司官网及优宁维商城所列产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500036927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2557369784","title":"优宁维:暂无计划向医药制造端延伸","url":"https://stock-news.laohu8.com/highlight/detail?id=2557369784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557369784?lang=zh_cn&edition=full","pubTime":"2025-08-05 16:54","pubTimestamp":1754384051,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维08月05日在投资者关系平台上答复投资者关心的问题。公司定位于生命科学一站式服务商,围绕“平台极致和抗体极致”战略,聚焦于为大学、科研院所、医院和生物医药企业的科研端提供生物试剂、设备、耗材及实验室综合技术服务,助力生命科学的发展与创新。基于上述战略定位,公司暂无计划向医药制造端延伸。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500027914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","159938","301166","09939","BK0250","BK1515"],"gpt_icon":0},{"id":"2556801713","title":"优宁维:公司参与投资的股权投资基金主要投向医疗健康、数字经济、先进制造等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2556801713","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556801713?lang=zh_cn&edition=full","pubTime":"2025-08-04 16:31","pubTimestamp":1754296281,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:介绍下贵公司的创投投资了哪几个主要企业,他们前景如何?优宁维(301166.SZ)8月4日在投资者互动平台表示,投资者您好,公司参与投资的股权投资基金主要投向医疗健康、数字经济、先进制造等领域。(记者 曾健辉)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080416324894ce5265&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080416324894ce5265&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0250","159760","301166","399260","159658","399262","560800"],"gpt_icon":0},{"id":"2556809768","title":"优宁维:公司陆续上线ERP系统等信息化系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2556809768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556809768?lang=zh_cn&edition=full","pubTime":"2025-08-04 16:27","pubTimestamp":1754296059,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维(301166)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司是否和ERP有合作?优宁维回复:投资者您好,公司高度重视信息化能力对于公司业务和管理方面的赋能,陆续上线了CRM、OMS订单管理系、ERP系统、WMS物流系统、LIMS系统等信息化系统,助力公司业务、研发、管理等方面效率的提升。谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400021454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765127008949,"stockEarnings":[{"period":"1week","weight":-0.0396},{"period":"1month","weight":-0.0423},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0399},{"period":"1year","weight":0.0152},{"period":"ytd","weight":0.1025}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海优宁维生物科技股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"9893人(较上一季度减少13.19%)","perCapita":"5753股","listingDate":"2021-12-28","address":"上海市杨浦区控江路1690号1505室","registeredCapital":"8666万元","survey":" 上海优宁维生物科技股份有限公司的主营业务是提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司的主要产品是生命科学试剂、生命科学仪器及耗材、综合技术服务。","listedPrice":86.06},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"优宁维,301166,优宁维股票,优宁维股票老虎,优宁维股票老虎国际,优宁维行情,优宁维股票行情,优宁维股价,优宁维股市,优宁维股票价格,优宁维股票交易,优宁维股票购买,优宁维股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}